Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-385 DDI with Fluconazole and Atorvastatin
NCT02093390Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- Apr 2014
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 1, open-label trial of tissue-plasminogen activator in prostate cancer (PCa) and endometriosis (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at Day 10, Area Under the Plasma Concentration Curve From Time Zero to Last Quantifiable Concentration at Day 10 and 1 more. Started Mar 2014; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)endometriosis
Beyond the preview
Go deeper on NCT02093390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02093390.